Lilly and Samsung fueled competition in biosimilar insulin market
Biosimilar developers will now aim for the insulin market. Their target is ‘Lantus,’ the one prescribed the most.
According to the industry concerned on the 24th, the first biosimilar of Lantus(insulin glargine) was developed by Lilly. The company acquired the sales approval of ‘Basaglar’ in Eu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
